Literature DB >> 18563170

Modulation of cystic fibrosis lung disease by variants in interleukin-8.

A D Hillian1, D Londono, J M Dunn, K A B Goddard, R G Pace, M R Knowles, M L Drumm.   

Abstract

Cystic fibrosis pulmonary disease is characterized by excessive and prolonged inflammation. CF Pulmonary disease severity exhibits considerable variation that, to some extent, appears to be due to the presence of modifier genes. Several components of the inflammatory response are known to have altered regulation in the CF lung. Genetic variants in 52 inflammatory genes were tested for associations with lung disease indices in a CF patient population (n=737) homozygous for the DeltaF508 cystic fibrosis transmembrane conductance regulator mutation. Variants in three inflammatory genes showed significant genotypic associations with CF lung disease severity, including IL8 and previously reported TGFbeta1 (P< or =0.05). When analyzed by gender, it was apparent that IL8 variant associations were predominantly due to males. The IL8 variants were tested in an additional CF population (n=385) and the association in males verified (P< or =0.01). The IL8 variants were in strong linkage disequilibrium with each other (R2> or =0.82), while variants in neighboring genes CXCL6, RASSF6 and PF4V1 did not associate (P> or =0.26) and were in weaker LD with each other and with the IL8 variants (0.01< or =R2< or =0.49). Studies revealed differential expression between the IL8 promoter variant alleles (P<0.001). These results suggest that IL8 variants modify CF lung disease severity and have functional consequences.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18563170      PMCID: PMC4255265          DOI: 10.1038/gene.2008.42

Source DB:  PubMed          Journal:  Genes Immun        ISSN: 1466-4879            Impact factor:   2.676


  48 in total

1.  Genomic control for association studies.

Authors:  B Devlin; K Roeder
Journal:  Biometrics       Date:  1999-12       Impact factor: 2.571

2.  Dysregulated cytokine production in human cystic fibrosis bronchial epithelial cells.

Authors:  A A Stecenko; G King; K Torii; R M Breyer; R Dworski; T S Blackwell; J W Christman; K L Brigham
Journal:  Inflammation       Date:  2001-06       Impact factor: 4.092

3.  Physical mapping of the CXC chemokine locus on human chromosome 4.

Authors:  N O'Donovan; M Galvin; J G Morgan
Journal:  Cytogenet Cell Genet       Date:  1999

Review 4.  Pharmacological approaches for the discovery and development of new anti-inflammatory agents for the treatment of cystic fibrosis.

Authors:  Michael W Konstan; Pamela B Davis
Journal:  Adv Drug Deliv Rev       Date:  2002-12-05       Impact factor: 15.470

Review 5.  Modifier genetics: cystic fibrosis.

Authors:  Garry R Cutting
Journal:  Annu Rev Genomics Hum Genet       Date:  2005       Impact factor: 8.929

6.  Increased in vivo transcription of an IL-8 haplotype associated with respiratory syncytial virus disease-susceptibility.

Authors:  D Hacking; J C Knight; K Rockett; H Brown; J Frampton; D P Kwiatkowski; J Hull; I A Udalova
Journal:  Genes Immun       Date:  2004-06       Impact factor: 2.676

7.  Inflammatory cytokines in cystic fibrosis lungs.

Authors:  T L Bonfield; J R Panuska; M W Konstan; K A Hilliard; J B Hilliard; H Ghnaim; M Berger
Journal:  Am J Respir Crit Care Med       Date:  1995-12       Impact factor: 21.405

Review 8.  The spectrum of cystic fibrosis mutations.

Authors:  L C Tsui
Journal:  Trends Genet       Date:  1992-11       Impact factor: 11.639

9.  Coordinate regulation of multiple human lymphokine genes by Oct-1 and potentially novel 45 and 43 kDa polypeptides.

Authors:  K Kaushansky; S G Shoemaker; C A O'Rork; J M McCarty
Journal:  J Immunol       Date:  1994-02-15       Impact factor: 5.422

10.  Haplotype mapping of the bronchiolitis susceptibility locus near IL8.

Authors:  Jeremy Hull; Kate Rowlands; Elizabeth Lockhart; Mike Sharland; Catrin Moore; Neil Hanchard; Dominic P Kwiatkowski
Journal:  Hum Genet       Date:  2003-11-06       Impact factor: 4.132

View more
  26 in total

Review 1.  Genetic variation and clinical heterogeneity in cystic fibrosis.

Authors:  Mitchell L Drumm; Assem G Ziady; Pamela B Davis
Journal:  Annu Rev Pathol       Date:  2011-10-17       Impact factor: 23.472

2.  Initial interrogation, confirmation and fine mapping of modifying genes: STAT3, IL1B and IFNGR1 determine cystic fibrosis disease manifestation.

Authors:  Heike Labenski; Silke Hedtfeld; Tim Becker; Burkhard Tümmler; Frauke Stanke
Journal:  Eur J Hum Genet       Date:  2011-07-06       Impact factor: 4.246

Review 3.  Genetic modifiers and oligogenic inheritance.

Authors:  Maria Kousi; Nicholas Katsanis
Journal:  Cold Spring Harb Perspect Med       Date:  2015-06-01       Impact factor: 6.915

4.  The influence of genetics on cystic fibrosis phenotypes.

Authors:  Michael R Knowles; Mitchell Drumm
Journal:  Cold Spring Harb Perspect Med       Date:  2012-12-01       Impact factor: 6.915

5.  Efficient delivery of RNA interference oligonucleotides to polarized airway epithelia in vitro.

Authors:  Shyam Ramachandran; Sateesh Krishnamurthy; Ashley M Jacobi; Christine Wohlford-Lenane; Mark A Behlke; Beverly L Davidson; Paul B McCray
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2013-04-26       Impact factor: 5.464

Review 6.  Cystic fibrosis: a clinical view.

Authors:  Carlo Castellani; Baroukh M Assael
Journal:  Cell Mol Life Sci       Date:  2016-10-05       Impact factor: 9.261

7.  Airway Mucosal Host Defense Is Key to Genomic Regulation of Cystic Fibrosis Lung Disease Severity.

Authors:  Deepika Polineni; Hong Dang; Paul J Gallins; Lisa C Jones; Rhonda G Pace; Jaclyn R Stonebraker; Leah A Commander; Jeanne E Krenicky; Yi-Hui Zhou; Harriet Corvol; Garry R Cutting; Mitchell L Drumm; Lisa J Strug; Michael P Boyle; Peter R Durie; James F Chmiel; Fei Zou; Fred A Wright; Wanda K O'Neal; Michael R Knowles
Journal:  Am J Respir Crit Care Med       Date:  2018-01-01       Impact factor: 21.405

8.  IL8 gene as modifier of cystic fibrosis: unraveling the factors which influence clinical variability.

Authors:  Larissa Lazzarini Furlan; Fernando Augusto Lima Marson; José Dirceu Ribeiro; Carmen Sílvia Bertuzzo; João Batista Salomão Junior; Dorotéia Rossi Silva Souza
Journal:  Hum Genet       Date:  2016-05-21       Impact factor: 4.132

9.  SARS coronavirus spike protein-induced innate immune response occurs via activation of the NF-kappaB pathway in human monocyte macrophages in vitro.

Authors:  Susan F Dosch; Supriya D Mahajan; Arlene R Collins
Journal:  Virus Res       Date:  2009-01-29       Impact factor: 3.303

10.  Identification of IFRD1 as a modifier gene for cystic fibrosis lung disease.

Authors:  YuanYuan Gu; Isaac T W Harley; Lindsay B Henderson; Bruce J Aronow; Ilja Vietor; Lukas A Huber; John B Harley; Jeffrey R Kilpatrick; Carl D Langefeld; Adrienne H Williams; Anil G Jegga; Jing Chen; Marsha Wills-Karp; S Hasan Arshad; Susan L Ewart; Chloe L Thio; Leah M Flick; Marie-Dominique Filippi; H Leighton Grimes; Mitchell L Drumm; Garry R Cutting; Michael R Knowles; Christopher L Karp
Journal:  Nature       Date:  2009-02-25       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.